GIA
NVCR icon

GHP Investment Advisors’s NovoCure NVCR Stock Holding History

GHP Investment Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-150
Closed -$2.13K – 919
2023
Q3 		$2.13K Hold
150
– – ﹤0.01% 843
2023
Q2 		$4.69K Sell
150
-1
-0.7% -$62 ﹤0.01% 777
2023
Q1 		$9.08K Hold
151
– – ﹤0.01% 703
2022
Q4 		$11.1K Hold
151
– – ﹤0.01% 670
2022
Q3 		$11K Hold
151
– – ﹤0.01% 663
2022
Q2 		$10K Hold
151
– – ﹤0.01% 684
2022
Q1 		$13K Buy
+151
New +$11.1K ﹤0.01% 675

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

GHP Investment Advisors's NVCR Position: Q4 2023 in Review

GHP Investment Advisors sold out of NovoCure (NVCR) in Q4 2023, closing a stake of 150 shares — an estimated $2.13K sold.

GHP Investment Advisors first reported a position in NVCR in Q1 2022 and held it in 7 quarters. The position peaked at $13K in Q1 2022. 219 funds tracked by Wall St. Rank hold NVCR as of Q4 2023.

  • GHP Investment Advisors reported no remaining NovoCure position as of Q4 2023 after selling out during the quarter.
  • GHP Investment Advisors sold 150 NovoCure shares in Q4 2023, an estimated $2.13K.
  • GHP Investment Advisors first reported a position in NovoCure in Q1 2022 and held it in 7 quarters.
  • GHP Investment Advisors's NovoCure position peaked at $13K in Q1 2022.
  • 219 funds tracked by Wall St. Rank held NovoCure as of Q4 2023.

Based on GHP Investment Advisors's 13F filing for Q4 2023, filed 26 Jan 2024.